Alto Neuroscience, Inc.ANRONYSE

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 83% recommend buying.

Consensus Rating

Buy

6 analysts·Limited coverage

83%

Rating Distribution

Strong Buy

00%

Buy

583%

Hold

117%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Price is near analyst consensus — limited near-term upside expected.

Bear Case

$16.00

+1%

Consensus

$16.00

+1%

Bull Case

$16.00

+1%

Price Range6 analysts

Low

Consensus

High

$16.00

Current Target

Current Price

$15.87

Upside to Target

$0.13

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-2.30(6 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev—

EPS—

FY2028

Rev—

EPS—

FY2029

Rev+427.14%

EPS—

Earnings Surprises

Beat rate:63%(5/8 quarters)

Avg surprise:-47.0%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Oct 20, 2025Robert W. Baird

Alto Neuroscience price target raised to $16 from $10 at Baird

Target:$16.00

+44.6%from $11.07

Oct 23, 2024Robert W. Baird

Alto Neuroscience (ANRO) PT Lowered to $10 at Baird

Target:$10.00

-31.2%from $14.53

Jun 20, 2024Robert W. Baird

Baird on Alto Neuroscience (ANRO): 'Incrementally positive on Phase 2 CIAS initiation'

Target:$32.00

+188.0%from $11.11

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance